Filing Details
Anika Therapeutics, Inc. (NASDAQ:ANIK) filed a Form 8-K with the Securities and Exchange Commission on July 14, 2026, disclosing a material event.
8k filedNASDAQ:ANIK
Anika Therapeutics, Inc. (ANIK) Reports Material Event to SEC
Filing Details Anika Therapeutics, Inc. (NASDAQ:ANIK) filed a Form 8-K with the Securities and Exchange Commission on July 14, 2026, disclosing a material event. Market Context…
Market Context
Anika Therapeutics, Inc.'s stock currently trades at $15.52 with a market capitalization of $207.1M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Anika Therapeutics, Inc.'s stock.
All SEC filings for Anika Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ANIK Stock Page
Frequently Asked Questions
Where can I read ANIK's SEC filings?
Browse all filings on our ANIK SEC filings page.
What types of SEC filings does Anika Therapeutics, Inc. file?
Public companies like Anika Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.